MIRA制药公司开始对Ketamir-2进行多剂量试验,一种口服氯胺酮模拟剂,用于治疗与化疗相关的神经疼痛,显示早期的安全和潜力。 MIRA Pharmaceuticals starts multiple-dose trial of Ketamir-2, an oral ketamine analog, for chemotherapy-related nerve pain, showing early safety and potential.

在单一剂量阶段取得积极结果之后,MIRA制药公司已开始对Ketamir-2第一阶段试验的多个上升剂量阶段,一种口服氯胺酮模拟剂,用于健康志愿者。 MIRA Pharmaceuticals has begun the multiple ascending dose phase of its Phase 1 trial for Ketamir-2, an oral ketamine analog, in healthy volunteers, following positive results from the single dose phase. 该研究在五天内每天检测150毫克至600毫克的剂量,迄今没有关于严重或剂量限制副作用的报告。 The study tests daily doses from 150 mg to 600 mg over five days, with no serious or dose-limiting side effects reported so far. 临床数据显示,Ketamir-2有效减少了老鼠的化疗诱发的神经病痛,超过现有治疗水平。 Preclinical data show Ketamir-2 effectively reduces chemotherapy-induced neuropathic pain in rodents, outperforming existing treatments. 该药物旨在提供一次不产生氯胺酮精神活性影响的每日口服选择。 The drug aims to provide a once-daily oral option without ketamine’s psychoactive effects. MIRA计划将Ketamir-2推进到第二阶段a试验,重点是化疗引起的外围神经病,这一疾病影响到多达70%的癌症患者,缺乏经林业发展局批准的治疗方法。 MIRA plans to advance Ketamir-2 into a Phase 2a trial focused on chemotherapy-induced peripheral neuropathy, a condition affecting up to 70% of cancer patients and lacking FDA-approved therapies.